Literature DB >> 33821690

Intuitive Staging Correlates With King's Clinical Stage.

Ahmad Al Khleifat1, Rubika Balendra2,3, Ton Fang1, Ammar Al-Chalabi1,4.   

Abstract

Background: Clinical stage in amyotrophic lateral sclerosis (ALS) can be assigned using King's staging with a simple protocol based on the number of CNS regions involved and the presence of significant nutritional or respiratory failure. It is important that the assigned clinical stage matches expectations, and generally corresponds with how a health care professional would intuitively stage the patient. We therefore investigated the relationship between King's clinical ALS stage and ALS stage as intuitively assigned by health care professionals.
Methods: We wrote 17 case vignettes describing people with ALS at different disease stages from very early limited disease involvement through to severe, multi-domain disease. During two workshops, we asked health care professionals to intuitively stage the vignettes and compared the answers with the actual King's clinical ALS stage.
Results: There was a good correlation between King's clinical ALS stage and intuitively assigned stage, with a Spearman's Rank correlation coefficient of 0.64 (p < 0.001). There was no difference in the intuitive stages assigned by practitioners of different types or at different levels of experience. Conclusions: Across a spectrum of ALS scenarios, King's clinical ALS stage corresponds to intuitive ALS stage as assigned by a range of health care professionals.

Entities:  

Keywords:  King’s stage; Prognosis; biomarker; clinical stage; prognostic; survival; ventilation

Mesh:

Year:  2021        PMID: 33821690      PMCID: PMC7611335          DOI: 10.1080/21678421.2020.1867181

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  28 in total

1.  Neuropsychological assessment in different King's clinical stages of amyotrophic lateral sclerosis.

Authors:  Francesca Trojsi; Gabriella Santangelo; Giuseppina Caiazzo; Mattia Siciliano; Teresa Ferrantino; Giovanni Piccirillo; Cinzia Femiano; Viviana Cristillo; Maria Rosaria Monsurrò; Fabrizio Esposito; Gioacchino Tedeschi
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-02-24       Impact factor: 4.092

2.  Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS.

Authors:  Patrick Oeckl; Claude Jardel; François Salachas; Foudil Lamari; Peter M Andersen; Robert Bowser; Mamede de Carvalho; Júlia Costa; Philip van Damme; Elizabeth Gray; Julian Grosskreutz; María Hernández-Barral; Sanna-Kaisa Herukka; André Huss; Andreas Jeromin; Janine Kirby; Magdalena Kuzma-Kozakiewicz; Maria Del Mar Amador; Jesús S Mora; Claudia Morelli; Petra Muckova; Susanne Petri; Koen Poesen; Heidrun Rhode; Anna-Karin Rikardsson; Wim Robberecht; Ana I Rodríguez Mahillo; Pamela Shaw; Vincenzo Silani; Petra Steinacker; Martin R Turner; Erdem Tüzün; Berrak Yetimler; Albert C Ludolph; Markus Otto
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-04-11       Impact factor: 4.092

Review 3.  Amyotrophic Lateral Sclerosis.

Authors:  Robert H Brown; Ammar Al-Chalabi
Journal:  N Engl J Med       Date:  2017-07-13       Impact factor: 91.245

Review 4.  Amyotrophic lateral sclerosis: moving towards a new classification system.

Authors:  Ammar Al-Chalabi; Orla Hardiman; Matthew C Kiernan; Adriano Chiò; Benjamin Rix-Brooks; Leonard H van den Berg
Journal:  Lancet Neurol       Date:  2016-10       Impact factor: 44.182

5.  Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study.

Authors:  Adriano Chiò; Andrea Calvo; Giacomo Bovio; Antonio Canosa; Davide Bertuzzo; Francesco Galmozzi; Paolo Cugnasco; Marinella Clerico; Stefania De Mercanti; Enrica Bersano; Stefania Cammarosano; Antonio Ilardi; Umberto Manera; Cristina Moglia; Riccardo Sideri; Kalliopi Marinou; Edo Bottacchi; Fabrizio Pisano; Roberto Cantello; Letizia Mazzini; Gabriele Mora
Journal:  JAMA Neurol       Date:  2014-09       Impact factor: 18.302

6.  Increased neurofilament light chain blood levels in neurodegenerative neurological diseases.

Authors:  Johanna Gaiottino; Niklas Norgren; Ruth Dobson; Joanne Topping; Ahuva Nissim; Andrea Malaspina; Jonathan P Bestwick; Andreas U Monsch; Axel Regeniter; Raija L Lindberg; Ludwig Kappos; David Leppert; Axel Petzold; Gavin Giovannoni; Jens Kuhle
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

7.  Comparison of the King's and MiToS staging systems for ALS.

Authors:  Ton Fang; Ahmad Al Khleifat; Daniel R Stahl; Claudia Lazo La Torre; Caroline Murphy; Carolyn Young; Pamela J Shaw; P Nigel Leigh; Ammar Al-Chalabi
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-01-05       Impact factor: 4.092

8.  A clinical tool for predicting survival in ALS.

Authors:  Jonathan A Knibb; Noa Keren; Anna Kulka; P Nigel Leigh; Sarah Martin; Christopher E Shaw; Miho Tsuda; Ammar Al-Chalabi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-07-04       Impact factor: 10.154

9.  ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS.

Authors:  Christopher Crockford; Judith Newton; Katie Lonergan; Theresa Chiwera; Tom Booth; Siddharthan Chandran; Shuna Colville; Mark Heverin; Iain Mays; Suvankar Pal; Niall Pender; Marta Pinto-Grau; Ratko Radakovic; Christopher E Shaw; Laura Stephenson; Robert Swingler; Alice Vajda; Ammar Al-Chalabi; Orla Hardiman; Sharon Abrahams
Journal:  Neurology       Date:  2018-09-12       Impact factor: 9.910

10.  Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis.

Authors:  Ashley R Jones; Naheed Jivraj; Rubika Balendra; Caroline Murphy; Joanna Kelly; Marie Thornhill; Carolyn Young; Pamela J Shaw; P Nigel Leigh; Martin R Turner; I Nick Steen; Paul McCrone; Ammar Al-Chalabi
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-02-07       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.